Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDLR | P01130 | 1/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688353 | 0.90 | MAPT (0.37) | LDLRPCSK9GAAMAPTTP53 | |
| SCHEMBL29455671 | 0.88 | ALDH1A1 (0.37) | LDLRPCSK9MAPT | |
| SCHEMBL19981438 | 0.88 | ALDH1A1 (0.37) | LDLRPCSK9MAPT | |
| SCHEMBL29308354 | 0.81 | LDLR (0.37) | LDLRPCSK9GAAMAPTTHRB | |
| SCHEMBL29308357 | 0.73 | LMNA (0.33) | LDLRPCSK9GAAMAPTTHRB | |
| SCHEMBL25847648 | 0.71 | KDM4E (0.33) | CYP1A2CYP2D6MAPT | |
| SCHEMBL29455614 | 0.70 | ATP1A1 (0.38) | LDLRPCSK9CYP1A2CYP2D6MAPT | |
| SCHEMBL29308351 | 0.66 | TP53 (0.47) | CYP1A2GAAMAPTTP53 | |
| SCHEMBL18854927 | 0.65 | KDM4E (0.32) | MAPT | |
| SCHEMBL19981447 | 0.64 | PDE2A (0.39) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037326-B2 | Diaryl-azole compound and formulation for controlling harmful organism | NIPPON SODA CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037326-B2 | Diaryl-azole compound and formulation for controlling harmful organism | CRY1, CRKL, CDC5L | LDLR 4189/4885PCSK9 4805/4885CYP1A2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.